While there are targeted treatments for triple positive breast cancers, lack of specific biomarkers for triple-negative breast cancers (TNBC) has hindered the development of therapies for this subset of cancers. In this study, we evaluated the anticancer properties of cardiac glycoside Digitoxin (Dtx) and its synthetic analog MonoD on breast cancer cell lines MCF-7 (estrogen receptor-positive breast cancer) and MDA-MB-468 (triple-negative breast cancer). Both cardiac glycosides, at concentrations within the therapeutic range, increased the fraction of cells in the G 0 /G 1 phase of the cell cycle, decreased viability, and inhibited the migration of MCF-7 and MDA-MB-468 cells. Both cardiac glycosides increased production of superoxide and induced apoptosis in both cell types. Reduced protein levels of nuclear factor kappa B and IkappaB kinase-beta were found in cardiac glycoside-treated cells, indicating that the cellular effects of these compounds are mediated via nuclear factor kappa B pathway. This study demonstrates the cytotoxic potential of digitoxin, and more importantly its synthetic analog MonoD, in the treatment of triple-positive breast cancer and more importantly the aggressive triple-negative breast cancer. Collectively, this study provides a basis for the reevaluation of cardiac glycosides in the treatment of breast cancer and more importantly reveals their potential in the treatment of triple-negative breast cancers.
Introduction
Breast cancer is a heterogeneous disease that can be subdivided into triple-positive breast cancer (TPBCs) or triplenegative breast cancers (TNBCs) on the basis of expression of molecular markers. TNBCs lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) and do not respond to hormonal therapies or to HER2-specific antibodies and inhibitors such as trastuzumab or lapatinib. TNBCs occur at a higher frequency in young premenopausal women with African ancestry and account for 15%-20% of all breast cancer cases. 1 TNBCs are aggressive with higher rates of relapse and shorter overall survival compared with other subtypes of breast cancer. Because of the lack of well-defined molecular targets, cytotoxic chemotherapy is currently the only treatment option for TNBCs. 2 For advanced disease, a number of clinical trials using drugs that target angiogenesis, poly-adenosine diphosphate (ADP)-ribose-polymerase (PARP), epidermal growth factor receptor (EGFR), phosoinositol-3 kinase (PI3K), mitogen-activated protein kinase (MAPK), checkpoint kinase (CHK), and histone-deacetylase (HDAC) pathways are ongoing, but preliminary data suggest that the clinical benefit from such therapies was still limited. 2 There is therefore an urgent need to identify new anticancer drugs that target breast cancer independent of their receptor status and against TNBCs in particular.
Digitoxin (Dtx), a cardenolide used to treat cardiac disorders, showed promise as an anticancer agent before concerns regarding its narrow therapeutic range prematurely tempered enthusiasm in relation to its tumoristatic potential. A few studies have evaluated the anticancer properties of Dtx alone or in combination with other potential anticancer drugs on breast cancers. Dtx alone can sensitize T47D breast cancer cells (ER + and PR + ) to anoikis 3 and has potent antiproliferative effects on several breast cancer cell lines, 4 and its effect can be potentiated with actein 5 or paclitaxel. 6 However, with regard to breast cancer subtypes, only one study compared the effect of Dtx on ER + versus ER − using three different cell lines isolated form Caucasian patients: MDA-MB-453 (ER − and Her2 overexpressing), MCF-7 (ER + and Her2 low), and BT474 (ER + and Her2 overexpressing). 6 While the study suggested that a combination of Dtx and Paclitaxel is a promising treatment for ER-negative breast cancer, there have not been any studies evaluating the effect of Dtx on TNBC from African descent.
In this study, we evaluated the anti-tumorigenic effect of the Dtx and its novel monosaccharidic analog MonoD on MCF-7 versus MDA-MB-468 cells. While the MCF-7 cell line was isolated from a pleural effusion of a 69-year-old Caucasian female patient from a metastatic site, the MDA-MB-468 cell line is a TNBC (ER − , PR − , and Her2 − ) cell line that was isolated from a pleural effusion of a 51-year-old black female patient with metastatic adenocarcinoma of the breast. 7 Our data demonstrate that Dtx and MonoD inhibit proliferation and migration and induce oxidative stress, cell-cycle arrest, and apoptosis of both breast cancer cells independent of their receptor status at a concentration within the therapeutic range. We believe that further exploration of this class of drugs may hold the promise for a suitable therapeutic strategy against TPBCs and TNBCs in patients from both African and Caucasian origin.
Materials and methods

Synthesis of MonoD
The β-D-Digitoxose (MonoD) form of Dtx was synthesized using a palladium-based de novo method as described previously by Iyer et al. 8 
Chemicals and reagents
Thiazolyl blue tetrazolium bromide (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)), cisplatin, sodium dichromate (Na 2 Cr 2 O 7 .2H 2 O) (Cr(VI)), Triton X-100, DNAse-free RNAse, and propidium iodide were obtained from Sigma Aldrich (St. Louis, MO). The oxidative probes 4,5-diaminofluorescein diacetate (DAF-2DA), dichlorofluorescein (DCF) diacetate, dihydroethidium (DHE), and the apoptosis dye Hoechst 33342 were obtained from Molecular Probes (Eugene, OR). Antibodies for PARP, caspase-9, p-Akt (Ser 473), total-Akt, p27, cyclin D3, cyclin-dependent kinase 2 (CDK2), p21, nuclear factor kappa B (NF-κB), and IkappaB kinase-beta (IKK-β) and peroxidase-labeled secondary rabbit and mouse antibodies were purchased from Cell Signaling Technology (Denvers, MA). Antibody for Bcl-2 was procured from Santa Cruz Biotechnology (Dallas, TX). Bicinchoninic acid (BCA) and SuperSignal ® West Pico chemiluminescent substrate were purchased from Thermo Fisher Scientific (Waltham, MA).
Preparation of anticancer drugs
Dtx and MonoD were stored as stock solution (10 mM) in dimethyl sulfoxide (DMSO) in glass containers. Final dilutions were prepared freshly in culture media before use. The control experiment contained the highest concentration (0.001%) of DMSO only. Cisplatin was prepared as stock solution (100 mM) in DMSO and stored in aliquots at −20°C.
Cell culture
The human breast cancer cell lines MCF-7 and MDA-MB-468 were obtained from American Type Culture Collection (Manassas, VA). Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM)/high glucose supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine, 100 U/ mL penicillin, and 100 mg/mL streptomycin. All cells were cultured in a 5% CO 2 environment at 37°C.
MTT assay
Cells were plated in 96-well cell-culture microplates (Costar, IL, USA) at ~2500 cells per well and incubated overnight in cell-culture medium. The cells were subsequently exposed to the appropriate concentration of drug or vehicle for 72 h in serum-free media. Cell viability was evaluated by the MTT assay. The absorbance of solubilized formazan was read at 570 nm using the BioTek Synergy plate reader (BioTek, VT, USA). In all cases, the highest concentration of DMSO was used in the control, and this concentration was maintained below 0.001% (v/v). This DMSO concentration did not show any significant antiproliferative effect.
Cell-cycle synchronization and analysis
Cells were synchronized in G 0 /G 1 phase by serum starvation. Briefly, 5 × 10 5 cells were plated overnight in a six-well plate in medium containing 1% FBS before culturing them in serum-free medium for 72 h, followed by restimulation with complete medium for control samples, and addition of drugs in complete medium for test samples. Cells were harvested after 72 h serum starvation for a serum-free control. Other samples were re-stimulated in complete medium with and without Dtx/MonoD for additional 24 h.
Cell-cycle analysis based on DNA content was performed as follows. Cells were harvested and washed twice with ice cold phosphate-buffered saline (PBS). Cells were then fixed in 2 mL of ice cold 70% ethanol for at least 24 h at −20°C. Cells were centrifuged, resuspended in 500 µL of propidium iodide staining solution (0.1% (v/v) Triton X-100, 2 mg DNAse-free RNAse A, and 400 µL of 500 µg/mL PI in 10 mL of PBS), and incubated at room temperature for 30 min. The cells were then analyzed with BD FACSCalibur (Becton Dickinson Immunocytometry, Mountain View, CA), Acea Novocyte 2060 (Acea Biosciences, San Diego, CA), and ModFit LT™ cycle analysis software (Verity Software, Topsham, ME). The cell-cycle distribution is shown as the percentage of cells containing G0/G1, S, and G2/M DNA as identified by propidium iodide staining. 
Apoptosis assay
Detection of reactive oxygen species and nitric oxide
Intracellular nitric oxide (NO), hydrogen peroxide (H 2 O 2 ), and superoxide (  YO 2 − ) production was determined by fluorometric analysis using specific probes DAF, DCF, and DHE, respectively, as described earlier. 9 Briefly, cells were incubated with the respective probe (10 µM) for 30 min at 37°C and analyzed for fluorescence intensity using a multi-well plate reader at the excitation/emission wavelengths of 495/515, 485/535, and 485/610 nm for DAF, DHE, and DCF, respectively.
Western blotting
Preparation of cell lysates and western blotting were performed as described previously. 10 Briefly, equal amount of protein per sample (40 µg) was resolved on a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a 0.45-mm nitrocellulose membrane (Pierce, Rockford, IL) using Trans-Blot Turbo™ Transfer System from Bio-Rad (Hercules, CA). The transferred membranes were blocked for 1 h in 5% non-fat dry milk in Tris buffered saline with Tween 20 (TBST; 0.05% Tween-20 in TBS) and incubated with the appropriate primary antibodies (dilution 1:1000) and horseradish peroxidase-conjugated isotype-specific secondary antibodies (dilution 1:5000). The immune complexes were detected by chemiluminescence imaged using myECL Imager (Thermo Fisher Scientific, Waltham, MA) and quantified by imaging densitometry using ImageJ software. Mean densitometry data from independent experiments were normalized to the control where indicated.
Wound healing assay (scratch assay)
Cells were plated at 3 × 10 5 cells/well in a 24-well plate and allowed to grow to 85%-90% confluence as a monolayer. Gently, the cells were scratched with a 1 mL sterile tip across the center of the well. Cells were washed thrice with PBS to remove the detached and loosely adhered cells and phase-contrast images were photographed as control. Cells were treated with Dtx and MonoD in medium containing 5% FBS for 24 h and photographed. The cell migration within 24 h was calculated by measuring the area of the scratch using ImageJ.
Statistic analysis
The IC 50 (drug concentrations inhibiting cell growth by 50%) were determined by interpolation from the doseresponse curves using a sigmoidal logistic three-parameter equation. Curve fitting was performed with Sigmaplot (V.11.0) software. The data represent mean ± SD from three or more independent experiments with triplicates or quadruplicates. Level of significance between different treatment groups relative to control was determined by one-way and two-way analyses of variance (ANOVAs); p < 0.05 was considered statistically significant.
Results
Digitoxin and MonoD inhibit viability of MCF-7 and MDA-MB-468 cells
Cells were seeded at 2500 cells/well and allowed to adhere overnight. Then, cells were treated with Dtx and MonoD (0, 10, 50, or 100 nM) in serum-free media for 24, 48, or 72 h. Cell viability was determined by the MTT assay. Figure 1 shows that both cardiac glycosides (CGs) inhibit the viability of MCF-7 and MDA-MB-468 breast cancer cells. The decrease in viability after 24 h in MCF-7 with 50 nM Dtx was comparable with 10 nM MonoD; and similarly, the decrease in viability with 100 nM Dtx was comparable with the viability with 50 nM MonoD. 
Digitoxin and MonoD arrest MCF-
Digitoxin and MonoD inhibit migration of MCF-7 and MDA-MB-468 cells
The effect of Dtx and MonoD on cell migration was assessed using monolayer scratch assay. 11 The rate of migration was calculated by measuring the total area of the scratch at 0 h and 24 h. The treatment was done in the presence of 5% FBS in order to provide the cells a stimulant for migration and minimize the interference from cellular apoptosis. Dtx (p < 0.05) and MonoD (p < 0.05) reduced the migration of MCF-7 by over 75% (Figure 3 
Digitoxin and MonoD increase the production of superoxide (  YO 2 − ) in MCF-7 and MDA-MB-468 cells
Reactive radicals including reactive oxygen species (ROS) and reactive nitrogen species (RNS) are known to play a crucial role in activating apoptosis. 12 A 4-electron reduction of oxygen to 1-electron form with the release of cytochrome c from the mitochondria during apoptosis is associated with production of superoxide. 13 Therefore, we assessed for cellular ROS-RNS levels in Dtx-and MonoDtreated MCF-7 and MDA-MB-468 cells (Figure 4) . While no significant change in the levels of nitric oxide and hydrogen peroxide was observed, both Dtx and MonoD induced higher levels of superoxide as assayed using DHE in both the breast cancer subtypes (p < 0.05).
Digitoxin and MonoD induce apoptosis in MCF-7 and MDA-MB-468 cells
Given that Dtx and MonoD reduce the viability/proliferation in both these breast cancer cells, we wanted to investigate the ability of these drugs to induce apoptotic cell death. Cells were treated with Dtx and MonoD (50 nM) in serum-free media for 24 h. Apoptotic cells were detected by Hoechst 33342 staining. Figure 5 shows that Dtx and MonoD induce apoptosis as characterized by nuclear condensation and fragmentation in MCF-7 and MDA-MB-468 cells. Moreover, as observed with the MTT assay, the effect of MonoD on MCF-7 cells was significantly higher (p < 0.05) as compared with Dtx. Both MCF-7 as well MDA-MB-468 showed same level of sensitivity to apoptotic stimuli by MonoD.
Validation of cell-cycle arrest and apoptosis by immunoblotting for protein markers
Apoptosis was confirmed by western blot analysis that showed a marked increase in cleaved PARP, a hallmark of apoptosis and caspase activation. 14, 15 Figure 6 shows that Dtx treatment showed a marked increase in cleaved PARP at 24 h in MCF-7 as compared to 12 h. However, MonoD had comparable levels of cleaved PARP in MCF-7 at 12 h as well as 24 h, suggesting that MonoD potentiated apoptosis faster as compared to Dtx. Bcl-2 is a pro-survival factor which prevents the release of cytochrome c from mitochondria, thereby inhibiting the activation of caspases and inhibiting apoptosis. 16 We observed decreased expression of Bcl-2 with a 24 h treatment in both cell lines. Both Dtx and MonoD treatment reduced the levels of pro-caspase-9 and showed an increase in cleaved caspase-9 fragments. The activated caspase-9 activates caspase-3 and caspase-7 downstream along the apoptotic pathway. 17 Akt activation has been shown to positively regulate cellular proliferation and negatively regulate apoptosis. 18 Dtx and MonoD treatment decreased Akt activation in MCF-7 cells, thereby potentiating apoptosis. Interestingly, both these drugs, and MonoD to a larger extent, caused an induction of Akt in MDA-MB-468. NF-κB is known to inhibit programmed cell death through the activation of target genes, which block the induction of apoptosis. 19 IKK-β upon activation phosphorylates IκB and liberates NF-κB bound to it, which is translocated to the nucleus to activate the target genes involved in the inhibition of apoptosis. 20 Both CGs showed downregulation of IKK-β and NF-κB over a period of 24 h. p27 is a key regulator of G1-S phase transition and its activity is often impaired in breast and other cancers, with loss of p27 being a strong indicator of poor prognosis particularly in breast cancer. 21 Both these drugs induced expression of p27 over 24 h. Cyclin D3 is another protein that regulates the cell-cycle progression from G1 to S phase by forming a complex with CDK4/6. 22 MCF-7 and MDA-MB-468 showed a downregulation of cyclin D3 with 24 h treatment, indicating impairment in the activity of cyclin D3-dependent kinases, thereby causing cellcycle arrest. CDK2 is a key regulator of G1-S phase progression by binding to cyclin E or cyclin A. 23 Our test drugs reduced the expression of CDK2, thereby blocking the cell-cycle progression from G1 to S phase. CDK inhibitor p21, in addition to its function as an inhibitor of proliferation, also acts as an inhibitor of apoptosis, thereby counteracting its function as a tumor suppressor. 24, 25 We observed a downregulation of p21, suggesting that p21 acts as an inhibitor of apoptosis in our system.
Discussion
Of the several subtypes of breast cancer, the hormonerefractory "triple-negative breast cancer" (TNBC; indicating lack of estrogen, progesterone, and HER2neu receptor expression) is less responsive to treatment and has a much worse prognosis as compared to receptor-positive breast cancer. 26, 27 The 5-year survival rate for TNBC is 77% versus 93% of women with other types of breast cancer, 28 emphasizing an unmet pressing need to identify novel compounds that can target this particular subtype of breast cancer. The chemotherapeutic potential of CGs and particularly Dtx has been surprisingly underinvestigated in TNBCs, given its ability to induce cytotoxicity in other cancer types. The therapeutic plasma levels of Dtx are considered to be in the range of 13-33 nM 4,29 and up to 46 nM. 6 An epidemiologic study showed that control patients were 10 times more likely to have recurrence of breast cancer as compared to patients who were administered digitalis. 30 Thus, digitoxin at therapeutic, non-toxic concentrations of CGs seems to be a promising anticancer drug. We have synthesized its monosaccharide analog MonoD that has higher cytotoxicity compared to the parent compound at the same concentration and can therefore exert potent anti-tumor effects at sub-physiologic doses as compared to Dtx in lung cancer. 8, 10 Here, we have demonstrated the anti-tumorigenic potential of Dtx as well as MonoD in TNBC.
In this study, we first demonstrated a concentrationdependent effect on the antiproliferative activity of Dtx and its synthetic analog MonoD on MCF-7 (triple positive) and MDA-MB-468 (triple negative) cell lines at clinically tolerated concentrations (Figure 1 ). While both CGs showed cytotoxic potential against breast cancers independent of receptor status, MonoD showed higher efficacy in MCF-7 as compared to Dtx. Several in vitro models of apoptotic cell death share the common features of cellcycle arrest and inhibition of migration, eventually leading to apoptosis. 31, 32 Both CGs significantly increased the percentage of cells in the G 0 /G 1 phase of the cell cycle ( Figure 2 ) and inhibited the migration of cancer cells (Figure 3) as measured by the scratch assay. This assay is a straight forward method to study cell migration in vitro that mimics migration of cells in vivo. 11 Reactive radicals, and ROS in particular, are considered to be pivotal mediators of apoptosis and is a feature of many effective chemotherapeutic agents. 33, 34 Both CGs were found to induce oxidative stress by increasing the production of superoxide (  YO 2 − ) without altering the production of H 2 O 2 or NO ( Figure 4 ). Increased production of  YO 2 − was reported previously for the cardenolide oleandrin in human melanoma cells. 35 Increased superoxide that causes tumor cell injury through mitochondrial disruption 36 partially explains the decreased cellular viability observed in our system. This notion is supported by the fact that both Dtx and MonoD decreased the levels of Bcl-2, a key pro-survival protein associated with mitochondrial integrity. 37 Induction of apoptosis by Dtx and MonoD was assessed by Hoechst staining ( Figure 5 ) and confirmed by western blot, which showed increased levels of protein markers associated with apoptosis such as cleaved PARP and cleaved caspase-9 ( Figure 6 ). The decrease in the levels of Bcl-2 indicates that apoptosis occurred via activation of the intrinsic pathway that is known to be activated by stress stimuli. 38 
Conclusion
In summary, we have demonstrated that Dtx and MonoD, previously shown to be effective cytotoxic agents against lung cancer, have great potential as a chemotherapeutic agent in breast cancer. Chemotherapeutic treatment options for cancer still remain limited, particularly for breast cancers that have no receptors that can be targeted. Therefore, there is an urgent need to synthesize novel anticancer drugs such as MonoD that can be effective against cancers independent of their receptor status. Furthermore, the effectiveness of MonoD against TNBCs from African origin is particularly exciting, given the dearth of effective therapeutic strategies that can combat this particular type of breast cancer. This study will form the basis for future investigation into the pathways associated with MonoD action and will allow for further characterization of CGs as a viable class of drugs to treat cancer.
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